Regional Analysis
Global Breast Lesion Localization Methods Market- Regional Insights
- North America is the largest market for breast lesion localization methods, with a market share of 39% in 2022, which is primarily due to the increasing prevalence of early-stage breast cancer detection through screening mammography in the region. According to the American Cancer Society, approximately 80% of breast cancers are found through mammograms done for routine screening. Screen-detected lesions are often non-palpable as they are too small to be felt by touch alone.
- Asia Pacific is the second-largest market for breast lesion localization methods, with a market share of 28.1% in 2022. This is due to the higher prevalence of palpable tumors in the overall breast cancer cases reported from countries such as India, China, and Indonesia. For example, according to article published by the American Cancer Society around 60% of Chinese and 65% of Indonesian women were initially diagnosed with palpable breast lumps.
- Europe is the third-largest market for breast lesion localization methods, with a share of 19.9% in 2022. The market growth is being driven due to increasing prevalence of breast cancer in the region. For instance, on August 5, 2023, according to the data published, by Elsevier B.V., a Dutch academic publishing company, there were 576,000 new cases of breast cancer in the World Health Organization (WHO) European Region in 2020.
Figure 1. Global Breast Lesion Localization Methods Market Share (%), By Region, 2023
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
U.S.: 
U.K. : 
India : 
